https://www.selleckchem.com/pr....oducts/Masitinib-(AB
3% and for operative time, 47%. The mean mMII was significantly (p less then 0.001) higher in patients with surgical complications (4.5 ± 5.6) and general medical complications (6.5 ± 7. compared to those without (3.8 ± 4.9). Our results were comparable to those reported in the original publication of Mirza et al. CONCLUSION The mMII appeared to be a valid measure of surgical invasiveness in our study population. It can be used in predictor models and to adjust for surgical case-mix when comparing outcomes in different st
Like
Comment
Share
